Many of the major components of the SPDR Select Healthcare ETF (AMEX: XLV) have been acting well technically and exhibiting patterns that argue for more upside directly. These include Johnson & Johnson (JNJ), Merck (MKR), Pfizer (PFE) and Eli Lilly (LLY). Let's expect continued strength in the ETF that next confronts a key 8-week resistance line, now at 25.35/40. If hurdled that will trigger upside follow-through towards my optimal target zone of 27.20/60.
For more of Mike Paulenoff, sign up for a Free 15-Day Trial to his ETF Trading Diary.
